



October 12, 2022

To whom it may concern,

Company: Japan Lifeline Co., Ltd.  
Representative: Keisuke Suzuki, President and CEO  
(Code: 7575 TSE Prime Market)  
Contact person: Kenji Yamada, Senior Vice President,  
Corporate Administration Headquarters  
(TEL. +81-3-6711-5200)

### **Japan Lifeline Launches a Series of In-House Products for Biliary-Pancreatic Endoscopy**

Japan Lifeline Co., Ltd. (“Japan Lifeline” or “the Company”) is pleased to announce that it will begin marketing several of its proprietary biliary-pancreatic products, including the cholangioscope and surrounding treatment tools “the DRES series”, from October 2022. The Company says that it will line up a series of medical devices used for diagnosis and treatment in the realm of biliary-pancreatic endoscopy to fully accelerate this new business. The products are scheduled to be launched after the 30th Japan Digestive Disease Week (JDDW2022) (October 27-30, 2022), where Japan Lifeline’s products will be exhibited.

The digestive organs can be broadly divided into three groups: the gastrointestinal tract (esophagus, stomach, and large intestine), liver, and bile-pancreas (gall bladder, bile duct, and pancreas). Diseases in the biliary-pancreatic group include bile duct stones, biliary cancer, and pancreatic cancer. The bile ducts and pancreatic ducts are the passageways for digestive fluids flowing from the liver and pancreas to the duodenum. If they become blocked by stones or cancer, various symptoms such as jaundice occur. The biliary and pancreatic ducts are commonly examined and treated under contrasting images using a cholangioscope. (ERCP\*<sup>1</sup>) Japan Lifeline estimates the domestic market for biliary-pancreatic endoscopy-related products to be worth approximately 29 billion yen in 2020, and to grow even further in the future.

Japan Lifeline has been developing its cholangioscope and other treatment tools based on its unique manufacturing technology for high-performance catheter shafts cultivated in the cardiovascular space. Japan Lifeline’s proprietary cholangioscope features the ability to reuse expensive endoscopes, typically disposable as for conventional cholangioscopes. Furthermore, the inner diameter of the forceps port inside the sheath is larger than that of conventional products, so that physicians can choose tools to use from a wider variety. The Company is expecting that these features will provide medical professionals with the benefits of improved efficiency and precision in diagnosis and treatment, in addition to cost advantages.

Japan Lifeline has promoted product development applying its proprietary technologies while strengthening its sales and marketing ability in the gastrointestinal space. The Company has introduced a colonic stent as its first product in the same space in 2017, a radiofrequency ablation needle for liver cancer treatment in 2019, and a gastro-duodenal stent in 2021. The Company is eager to further develop products for biliary-pancreatic endoscopy to nurture its gastrointestinal business as the second pillar following its mainstay cardiovascular.

\*1 Endoscopic Retrograde Cholangiopancreatography: A procedure in which a contrast catheter is inserted through an endoscope into the bile and pancreatic ducts to provide a contrast image inside them for diagnostic purposes. Usually, physicians make treatment on found lesions at the same time.

[Attachment] List of Biliary-Pancreatic Products to be Launched

Category	Product Name	Launch Schedule
Cholangioscope	DRES Scope (Steerable Model)	October 2022
	DRES Slim Scope (Fix Model)	October 2022
	DRES Console	October 2022
	DRES CMOS Camera (Small Endoscope)	October 2022
Treatment tools	DRES ERCP Cannula	October 2022
	DRES Stone Basket	Fourth Quarter of FYE March 2023
	DRES Forceps	October 2022
	RIGEL Bile Duct Dilation Balloon	October 2022
	REGULUS Tube Stent for Bile Duct	August 2022 (Launched)



DRES Cholangioscope image